Commentary on "Noninvasive detection of multidrug resistance in patients with hematological malignancies: are we there yet?".

Jerusalem, Guy; Beguin, Yves

doi:10.1016/S1526-9655(11)70232-9

Article (Scientific journals)

Commentary on "Noninvasive detection of multidrug resistance in patients with hematological malignancies: are we there yet?".

Jerusalem, Guy; Beguin, Yves

2002 • In Clinical Lymphoma, 2 (4), p. 249

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/21188

DOI
10.1016/S1526-9655(11)70232-9

PubMed
15852545

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

174.pdf

Publisher postprint (135.98 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Contrast Media; Diagnostic Imaging/methods; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Hematologic Neoplasms/drug therapy/pathology/radionuclide imaging; Humans; Male; Neoplasm Staging; Positron-Emission Tomography; Risk Assessment; Sensitivity and Specificity

Disciplines :

Hematology

Author, co-author :

Jerusalem, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale

Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Language :

English

Title :

Commentary on "Noninvasive detection of multidrug resistance in patients with hematological malignancies: are we there yet?".

Publication date :

2002

Journal title :

Clinical Lymphoma

ISSN :

1526-9655

Publisher :

Cancer Information Group, Dallas, United States - Texas

Volume :

Issue :

Pages :

249

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 07 September 2009

Statistics

Number of views

36 (3 by ULiège)

Number of downloads

4 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Kostakoglu L. (2002) Noninvasive detection of multidrug resistance in patients with hematological malignancies: Are we there yet?. Clin. Lymphoma 2:242-248.
Piwnica-Worms D., Chiu M.L., Budding M. (1993) Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 53:977-984.
Dimitrakopoulou-Strauss A., Strauss L.G., Goldschmidt H. (1995) Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur. J. Nucl. Med 22:434-442.
Dalton W.S. (1997) Alternative (non-P-glycoprotein) mechanisms of drug resistance in non-Hodgkin’s lymphoma. Hematol. Oncol. Clin. North Am 11:975-986.
Belhocine T., Hustinx R., Jerusalem G. (2000) 99mTc rh-Annexin (ApomateTM) as a marker of apoptosis resulting from chemotherapy preliminary results. J. Nucl. Med , (Abstract #1154); 41.
Front D., Bar-Shalom R., Mor M. (2000) Aggressive non-Hodgkin lymphoma: Early prediction of outcome with 67Ga scintigraphy. Radiology 214:253-257.
Romer W., Hanauske A.R., Ziegler S. (1998) Positron emission tomography in non-Hodgkin’s lymphoma: Assessment of chemotherapy with fluorodeoxyglucose. Blood 91:4464-4471.
Jerusalem G., Beguin Y., Fassotte M.F. (2000) Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin’s lymphoma. Haematologica 85:613-618.
Kostakoglu L., Leonard R., Coleman C. (2001) FDG-PET after first cycle of chemotherapy predicts outcome at one year in aggressive lymphoma and Hodgkin’s disease. J. Nucl. Med , (Abstract #441); 42.